HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

10074-G5

structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxadiazoles: 146
        10074-G5: 2

Experts

1.	Prochownik, Edward V: 2 articles (01/2014 - 12/2010)
2.	Frenzel, Anna: 1 article (01/2014)
3.	Henriksson, Marie Arsenian: 1 article (01/2014)
4.	Larsson, Karin: 1 article (01/2014)
5.	Müller, Inga: 1 article (01/2014)
6.	Oliynyk, Ganna: 1 article (01/2014)
7.	Westwood, Nicholas J: 1 article (01/2014)
8.	Zirath, Hanna: 1 article (01/2014)
9.	Beumer, Jan H: 1 article (12/2010)
10.	Clausen, Dana M: 1 article (12/2010)

Related Diseases

1.	Neuroblastoma 01/01/2014 - "Importantly, 10074-G5 and 10058-F4 were the most efficient in inducing neuronal differentiation and lipid accumulation in MYCN-amplified neuroblastoma cells. "
2.	Neoplasms (Cancer) 12/01/2010 - "The lack of antitumor activity probably was caused by the rapid metabolism of 10074-G5 to inactive metabolites, resulting in tumor concentrations of 10074-G5 insufficient to inhibit c-Myc/Max dimerization. " 12/01/2010 - "The plasma half-life of 10074-G5 in mice treated with 20 mg/kg i.v. was 37 min, and peak plasma concentration was 58 μM, which was 10-fold higher than peak tumor concentration. "
3.	Burkitt Lymphoma (Burkitt's Lymphoma) 12/01/2010 - "In vitro, 10074-G5 inhibited the growth of Daudi Burkitt's lymphoma cells and disrupted c-Myc/Max dimerization. "

Related Drugs and Biologics

1.	Lipids